ArticleTranslational oncology2008
CHFR: A Novel Mitotic Checkpoint Protein and Regulator of Tumorigenesis.
Article in Translational oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Integrative bioinformatics and machine learning approaches identify novel diagnostic signatures for oxaliplatin-resistant colorectal cancer.International journal of colorectal disease · 2026Article
- CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial.NPJ breast cancer · 2025Article
- Development of an optimized, non-stem cell line for intranasal delivery of therapeutic cargo to the central nervous system.Molecular oncology · 2024Article
- Aurora kinase A induces migration and invasion by inducing epithelial-to-mesenchymal transition in colon cancer cells.BMB reports · 2022Article
- CHFR and Paclitaxel Sensitivity of Ovarian Cancer.Cancers · 2021Article
- Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment.World journal of gastrointestinal oncology · 2021Review
- Identification of a Novel Epigenetic Signature CHFR as a Potential Prognostic Gene Involved in Metastatic Clear Cell Renal Cell Carcinoma.Frontiers in genetics · 2021Article
- Silencing of CHFR Sensitizes Gastric Carcinoma to PARP Inhibitor Treatment.Translational oncology · 2020Article
- DNA replication and mitotic entry: A brake model for cell cycle progression.The Journal of cell biology · 2019Review
- CHFR Promoter Hypermethylation Is Associated with Gastric Cancer and Plays a Protective Role in Gastric Cancer Process.Journal of Cancer · 2019Review
- Association of CHFR Promoter Methylation with Treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic Colorectal Cancer.Neoplasia (New York, N.Y.) · 2019Article
- Clinicopathological significance ofOncotarget · 2018Article
- Clinicopathological significance ofOncotarget · 2017Article
- Involvement of multiple cellular pathways in regulating resistance to tamoxifen in BIK-suppressed MCF-7 cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Aurora-A Kinase as a Promising Therapeutic Target in Cancer.Frontiers in oncology · 2015Review
- Novel piperazine-based compounds inhibit microtubule dynamics and sensitize colon cancer cells to tumor necrosis factor-induced apoptosis.The Journal of biological chemistry · 2014Article
- Epigenetic silencing of checkpoint with fork-head associated and ring finger gene expression in esophageal cancer.Oncology letters · 2014Article
- Article
- CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation.The Journal of biological chemistry · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Checkpoint with FHA and RING finger domains (CHFR) was first recognized as an early mitotic checkpoint protein that delayed the cell cycle in response to microtubule-targeting drugs. It is an E3 ubiquitin ligase that ubiquitinates target proteins to direct them to the proteasome for degradation or to alter their activity. To date, however, the downstream target proteins critical to CHFR's normal cellular functions largely remain unidentified with the exception of the key mitosis regulators, and oncogenes, PLK1 and Aurora A kinases. Rapidly growing evidence in mice, primary human tumors, and mammalian cell culture models indicate that CHFR may also function as a potent tumor suppressor. Interestingly, studies reported to date suggest that CHFR both controls a novel prophase checkpoint early in mitosis and regulates chromosome segregation later in mitosis to maintain genomic stability. In addition, loss of CHFR sensitizes cancer cells to microtubule poisons, altering chemoresponsiveness to taxanes and making it a potential biomarker for chemotherapeutic response. Importantly, CHFR may be one of the few proteins that are required for regulating the cell cycle and maintaining genomic instability to inhibit tumorigenesis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.